Status:
UNKNOWN
Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome
Lead Sponsor:
University of Padova
Conditions:
Cirrhosis
Type 1 Hepatorenal Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
It is well known that terlipressin and albumin improve renal function in patients with cirrhosis and type 1 HRS. In previous studies terlipressin has been used either as intravenous boluses moving fro...
Eligibility Criteria
Inclusion
- Patients with cirrhosis and type 1 HRS
Exclusion
- HCC beyond the Milan Criteria,septic shock (systolic arterial pressure \< 90 mmHg,
- Significant heart or respiratory failure,
- Peripheral arteriophaty clinically significant,
- Previous heart stroke or significant alteration of the ECG
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2015
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00742690
Start Date
May 1 2005
End Date
March 1 2015
Last Update
October 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liver Unit, General Hospital
Padua, Italy, 35100